Pharmacological management of acute radiation morbidity.
BACKGROUND
The acute radiation morbidity may be a serious problem for the patient and may be decreased by pharmacological approaches.


METHODS
A database research (Medline, Cancerlit, DIMDI, etc.) was performed in order to obtain pharmacological approaches to decrease the acute radiation morbidity. The evaluation was focused on therapeutic principles but not on special drugs.


RESULTS
Different approaches may be chosen to protect healthy tissues from the effects of ionizing radiation: 1. administration of cyto- or radioprotective agents prior to irradiation, 2. administration of agents to avoid additional secondary toxicity by inflammation or superinfection during the treatment cycle (supportive care) and 3. administration of rescue agents, such as bone marrow CSFs or hyperbaric oxygen (HBO), after therapy. For radioprotection, there are reports on cellular protection by vitamine E, vitamine C, beta carotene, ribose-cysteine, glutamine, Mgcl2/adenosine triphosphate and WR-2721 (amifostine). In general, preclinical studies show that the combination of pretreatment with amifostine, irradiation, and G-CSF after radiation enhances hematologic recovery. Assessment of these combined effects, including local supportive therapies, merits further clinical investigation. There are data from prospective studies as well as from empirical clinical experience, that radioprotection and clinical supportive care may reduce the treatment related morbidity by 10 to 30% either.


CONCLUSIONS
A further improvement of the therapeutic ratio is to be expected by systemically combined application of radioprotectors, supportive care and rescue agents.
Zimmermann
J S
JS
Klinik für Strahlentherapie (Radioonkologie), Christian-Albrechts-Universität Kiel.
Kimmig
B
B
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D019992:Databases as Topic; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D006931:Hyperbaric Oxygenation; D007249:Inflammation / Q000517:prevention & control; D016239:MEDLINE; D009017:Morbidity; D011832:Radiation Injuries / Q000188:drug therapy / Q000453:epidemiology* / Q000628:therapy*; D011839:Radiation, Ionizing; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects*; D014815:Vitamins / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011837:Radiation-Protective Agents; D014815:Vitamins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor